by Richard Daverman, PhD
January 28, 2014 -- AstraZeneca and the Shanghai Institutes of Biological Sciences (SIBS) agreed to collaborate on a basic research project in cardiovascular disease. The two entities will seek to understand the development process for coronary vessels. The collaboration will focus on vessels that supply blood to the heart and will also attempt to regenerate the main branch to the heart. The ultimate goal of the project is to develop innovative treatments for cardiovascular disease. More details....
Stock Symbol: (NYSE: AZN)
Help employers find you! Check out all the jobs and post your resume.
